key: cord-0797784-dy0hhctx authors: Hassert, Mariah; Geerling, Elizabeth; Stone, E. Taylor; Steffen, Tara L.; Feldman, Madi S.; Class, Jacob; Richner, Justin M.; Brien, James D.; Pinto, Amelia K. title: mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2 date: 2020-08-07 journal: bioRxiv DOI: 10.1101/2020.08.07.241877 sha: 9350c9f9be61035b3c26178042543783aad805c8 doc_id: 797784 cord_uid: dy0hhctx The novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic resulting in nearly 20 million infections across the globe, as of August 2020. Critical to the rapid evaluation of vaccines and antivirals is the development of tractable animal models of infection. The use of common laboratory strains of mice to this end is hindered by significant divergence of the angiotensin-converting enzyme 2 (ACE2), which is the receptor required for entry of SARS-CoV-2. In the current study, we designed and utilized an mRNA-based transfection system to induce expression of the hACE2 receptor in order to confer entry of SARS-CoV-2 in otherwise non-permissive cells. By employing this expression system in an in vivo setting, we were able to interrogate the adaptive immune response to SARS-CoV-2 in type 1 interferon receptor deficient mice. In doing so, we showed that the T cell response to SARS-CoV-2 is enhanced when hACE2 is expressed during infection. Moreover, we demonstrated that these responses are preserved in memory and are boosted upon secondary infection. Interestingly, we did not observe an enhancement of SARS-CoV-2 specific antibody responses with hACE2 induction. Importantly, using this system, we functionally identified the CD4+ and CD8+ peptide epitopes targeted during SARS-CoV-2 infection in H2b restricted mice. Antigen-specific CD8+ T cells in mice of this MHC haplotype primarily target peptides of the spike and membrane proteins, while the antigen-specific CD4+ T cells target peptides of the nucleocapsid, membrane, and spike proteins. The functional identification of these T cell epitopes will be critical for evaluation of vaccine efficacy in murine models of SARS-CoV-2. The use of this tractable expression system has the potential to be used in other instances of emerging infections in which the rapid development of an animal model is hindered by a lack of host susceptibility factors. express the hACE2 in mice [2, [15] [16] [17] [18] [19] [20] [21] . Various strategies have been employed by multiple groups to facilitate the expression of hACE2 in mice, from CRISPR/Cas9 mediated hACE2 transgenics [2, 15, [18] [19] [20] [21] , to adenovirus [16] or adeno associated virus (AAV) expressing hACE2 [17] . SARS-CoV-2 intranasal infections in these systems have achieved detectable virus in the lungs and trachea leading to viral pneumonia histologically [16, 17, 22] . Alternatively, targeted mutagenesis of the SARS-CoV-2 spike protein, facilitating enhanced interactions with murine ACE2, results in a similar phenotype [23] . Golden Syrian hamsters also offer a potential avenue to explore vaccines and therapeutics against SARS-CoV-2 and multiple groups have found that SARS-CoV-2 efficiently replicates in the nasal mucosa, bronchial epithelial cells and isolated areas of the lungs of hamsters and this viral replication results in pathological lesions similar to those found in COVID-19 patients [14, 24] . Interestingly, one of these groups has reported this as a transmission model [14] . However due to the lack of reagents at this time, hamster models have had limited utility in the studies of immune correlates of protection from infectious diseases [25] . By developing an mRNA delivery platform to express hACE2 in mice, we have established a unique and highly adaptable murine model for studying SARS-CoV-2 infection. Using this model, we were able to characterize the murine adaptive immune response generated against SARS-CoV-2. We noted many significant benefits of the mRNA system for the development of a susceptible animal model for SARS-CoV-2, including rapid development of a susceptible mouse. The transfected RNA is highly durable, as we were able to detect mRNA expression in culture at high levels for at least 4 days following transfection. The transfection treatment can also be given repeatedly as the mRNA is poorly immunogenic. Utilizing the C57BL/6 type 1 interferon receptor deficient (Ifnar1 -/-) mice transfected with hACE2 mRNA, we have demonstrated that these mice are susceptible to a transient infection and can generate SARS-CoV-2 specific adaptive immune responses. We have been able use this system to identify both neutralizing antibodies and virus specific T cell responses. In this study we have identified nine CD8 + and six CD4 + H2 b restricted SARS CoV-2-specific T cell epitopes. These results demonstrate the development of a novel animal model for SARS-CoV-2 where hACE2 is expressed by mRNA and its utility in studying the adaptive immune responses to SARS CoV-2. To generate a construct which could produce robust expression of hACE2 mRNA, we used a pUC57 vector backbone consisting of four core components: 1) a type II T7 promoter for a high transcription rate in vitro and the production of RNA transcripts with homogeneous 5' and 3' termini; 2) a beta globin 5'UTR for optimized mRNA expression within mammalian cells; 3) 3' UTR from alpha globin for mRNA stability and 4) A 153 base adenosine nucleotide stretch as the polyA tail. Into this backbone, we cloned either the coding sequence for hACE2 or green fluorescent protein (GFP), as a control ( Figure 1B ). mRNA from either construct was then generated using a T7 ARCA in vitro transcription reaction. To demonstrate the stability of transcribed hACE2 mRNA, murine fibroblast 3T3 cells were transfected with the in vitro transcribed and purified GFP or hACE2 mRNA. At 48, 72 and 96 hours post-transfection, expression of hACE2 was measured by qRT-PCR ( Figure 1C ). For hACE2, the qRT-PCR data revealed that we were able to detect stable transfected hACE2 mRNA in the 3T3 cells for four days, with only a minimal decline in expression levels over that time period. For at least 96 hours post-transfection, the expression level of hACE2 in this hACE2 transfected cell line was similar to the mRNA expression of hACE2 we detected highly SARS-CoV-2 susceptible Calu-3 and Vero-E6 cell lines ( Figure 1C) . With the cells transfected with the GFP expressing mRNA construct, we performed flow cytometry and demonstrated that we could achieve greater than 90 percent transfection efficiency, and that the GFP expression was maintain for at least 72 hours (Supplemental Figure 1) . We attempted to measure hACE2 expression on hACE2 mRNA transfected 3T3 cells by flow cytometry in a similar manner. However, due to high antibody cross-reactivity between hACE2 and the murine cognate mACE2, after evaluation of six commercially available monoclonal and polyclonal antibodies, we concluded that mACE2 and hACE2 could not be distinguished in this manner and were unable to confirm hACE2 expression in our transfected 3T3 cells (data not shown). These results demonstrated that we were able to generate an mRNA vector expression system and deliver hACE2 to non-hACE2 expressing murine 3T3 cells, resulting in RNA expression levels similar to that observed in susceptible cell lines (Calu-3 and Vero-E6), and that the expression was stable for at least 96 hours. We next confirmed that expression of hACE2 by our mRNA construct conferred susceptibility of SARS-CoV-2 in murine cells by infecting the hACE2 or GFP transfected 3T3 cells with SARS-CoV-2 ( Figure 1D) . The hACE2 or GFP mRNA transfected cells were each plated into separate 6 well plates, and 24 hours after transfection, they were infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 0.01 . The infected cells were harvested at 24, 48, and 72 hours post infection and the viral genomes were quantified by qRT-PCR. The 3T3 cells transfected with the hACE2 had more virus detected at every time point post infection with approximately four logs higher viral genome copies within the cells as compared to the cells that had been transfected with the GFP expressing mRNA ( Figure 1D) . These results demonstrate that the transfection of murine cells with hACE2 mRNA confers susceptibility to infection with SARS-CoV-2. Understanding the role of the antigen specific T cell and antibody response against SARS-CoV-2 is critical for the development of safe and effective vaccines. Studies with murine hepatitis virus (MHV) A59, a natural mouse coronavirus pathogen [26] , concluded that a T cell response in combination with an antibody response was critical for controlling a coronavirus infection [27] . Additionally, studies into SARS-CoV and MERS-CoV suggest that the receptor binding domain (RBD) of the spike glycoprotein is likely the most effective target for current antibody-based vaccines against SARS-CoV-2. However, these SARS-CoV and MERS-CoV vaccine studies also noted that there is a concern that a vaccine directed solely against the spike glycoprotein will induce viral escape [28, 29] , and a successful vaccine should contain both a strong T cell response for early viral control, and neutralizing antibody for viral clearance [30] [31] [32] . Therefore, understanding the role of the T cell as well as the antibody response against SARS CoV-2 will be critical for the development, testing and evaluation of future vaccines. To begin to identify the immune correlates of protection we used the hACE2 mRNA transfection system to study the adaptive immune response to SARS-CoV-2 in type I interferon receptor 1 deficient (Ifnar1 -/-) mice (Figure 2) . We chose to use the Ifnar1 -/mice, because, like other viral infections, coronaviruses encode genes which dampen or block the type I IFN response creating a more susceptible environment for the establishment of infection [33, 34] . Studies with multiple viruses have shown that the loss of IFNAR, and therefore the significant dampening of IFN stimulating gene production, results in IFNAR deficient cells being highly susceptible to viral infections [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . Therefore, for the reported SARS-CoV-2 animal studies, we have used Ifnar1 -/mice. In these studies, we followed a prime boost strategy (Figure 2A) , similar to what would be done for a vaccine, so to enhance the detection of the immune response to SARS-CoV-2 in the Ifnar1 -/mice. First, the mice were transfected with 10 μg of mRNA encoding either hACE2 or GFP as a control. Twentyfour hours after mRNA in vivo delivery, we infected the hACE2 or GFP transfected Ifnar1 -/mice with To examine the antibody response directed against SARS-CoV-2, we performed an indirect ELISA against the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, a target of the neutralizing antibody response in both mice and humans [16, [45] [46] [47] . To quantify the anti-RBD antibody response, we compared the polyclonal sera from naïve Ifnar1 -/mice, to that of the SARS-CoV-2 infected Ifnar1 -/mice transfected with either the hACE2 or GFP mRNA ( Figure 2B ). We noted that only the Ifnar1 -/mice that had been infected with SARS CoV-2 were able to bind RBD. As expected, we saw no RBD binding from sera collected from naïve mice. However, analysis of the area under the curve (AUC) showed there were no detectible differences between the SARS CoV-2 infected Ifnar1 -/mice that had received GFP and hACE2 mice at either time point. While there were SARS-CoV-2 RBD specific antibodies present in both the infected GFP and hACE2 transfected mice, we were interested to determine if there was a difference in the neutralization capacity of the antibody response generated in the hACE2 transfected mice as compared to the GFP transfected controls. To test this, we performed focus reduction neutralization (FRNT) assays on the serum samples ( Figure 2C) . Briefly, serum from each mouse was serially diluted and combined with ~100 FFU of SARS-CoV-2 for one hour before the antibody-virus complex was added to a monolayer of Vero cells. After 24 hours of infection, the cells were fixed and stained with anti-SARS polyclonal guinea pig sera then stained with horseradish peroxidase-conjugated goat anti-guinea pig IgG. Foci from infected cells were visualized and counted using an EliSpot plate reader. Similar to the results of the ELISA, serum from naïve Ifnar1 -/mice was not able to neutralize SARS-CoV-2 ( Figure 2C) . Analysis of the neutralization curves and FRNT50 values from the serum collected showed that both the hACE2 and GFP transfected Ifnar1 -/mice were able to generate neutralizing antibodies, and there were no differences in the neutralization abilities of the serum collected at this time point(average EC50 values of 0.00096 and 0.00032, respectively). From the RBD ELISA data and FRNT data, we concluded that Ifnar1 -/mice infected with SARS CoV-2 can generate an antibody response to the virus and this response is independent of the hACE2 expression. Using the prime boost protocol outline in Figure 2A we examined the CD8 + T cell and CD4 + T cells from the blood after primary infection, and boost, by intracellular cytokine staining for the detection of interferon gamma (IFN-g) in response to anti-CD3 stimulation ( Figure 2D and Supplemental Figure 2 ). During the acute infection the IFN-g production in both the CD4 + and CD8 + T cells isolated from both the GFP and hACE2 transfected group were only slightly above the background of unstimulated cells isolated from the same group of mice and were not significantly different from one another. However, following the second infection with SARS-CoV-2 the IFN-g response was significantly higher in the Ifnar1 -/mice that were transfected with hACE2 (average CD8 + response= 2.25% and average CD4+ response= 2.01%) as compared to GFP (average CD8 + response= 0.61% and average CD4+ response= 0.38%) (p=0.0159). Importantly, we did not see a significant increase in the IFN-g responses from the CD4 + or CD8 + T cell in the boosted GFP mice as compared to the GFP mice following primary infection. This suggests that GFP transfected mice did not have an amnestic T cell response upon boost with SARS- The results of these studies indicate that the expression of hACE2 on the murine cells allows SARS-CoV-2 to enter the murine cells and undergo viral replication. This viral replication provides the antigen processing and presentation pathways access to the SARS-CoV-2 proteins. The proteins can then be either directly or cross-presented to T cells for the development of a robust response. This result is supported both by in vitro studies in the 3T3 cells ( Figure 1D ) and the in vivo T cell and FRNT studies ( Figure 2 ). Combining these studies suggests that hACE2 expression delivered by the mRNA construct allows virus entry and replication which is required for the production of viral epitopes needed to stimulate a T cell response. To test whether mRNA expression of hACE2 would allow the detection of infectious virus output, we followed a similar protocol to the one we had used in the adaptive immune studies where we administered 10 μg of the hACE2 mRNA or control GFP mRNA to Ifnar1 -/mice one day prior to infection. 24 hours post transfection, the Ifnar1 -/mice receiving either the hACE2 or the GFP mRNA constructs were infected with 5x10 4 FFU per mouse using a combined IV and IN route. Three days post SARS-CoV-2 infection, the mice were harvested and viral titers were measured in the brain, kidney, spleen, liver, lung and whole blood both by qRT-PCR and by focus forming assay (FFA). We were able to detect viral genome copies in the transfected Ifnar1 -/mice, however we did not detect differences in viral genome copies between the hACE2 and the GFP recipient mice (Supplemental Figure 3A -F). Additionally, we did not detect infectious virus in any organ from either group of mice by focus forming assay (FFA) (data not shown). While these studies suggest that the hACE2 mRNA transfection into the Ifnar1 -/mice did not increase the susceptibility of the Ifnar1 -/mice to SARS-CoV-2 it is possible that the dose and route of infection as well as the harvest time points we chose for these studies were not optimal for detection of infectious virus. Previous studies have shown that administration of higher doses of virus by the intranasal route did lead to the detection of virus in mice which had been induced to express hACE2 through the administration of an adeno-associated virus vector or recombinant Adenovirus [2, [15] [16] [17] [18] [19] [20] [21] [22] . While in the current study we chose low dose administration of virus to focus on immune responses future studies with higher doses of virus, similar to those published in other mouse models [2, [15] [16] [17] [18] [19] [20] [21] [22] can be administered to determine the utility of this model for SARS-CoV-2 pathogenesis. Additionally, future studies with alternate routes will be useful in determining if the delivery of mRNA expressing hACE2 can be used to develop a mouse model to study virus pathogenesis in specific tissues. While the mRNA delivery of hACE2 followed by infection with 5x10 4 FFU of SARS-CoV-2 did not allow our group to study viral pathogenesis in Ifnar1 -/mice, the delivery of mRNA hACE2 to our murine model allowed for the induction of a strong CD4 + and CD8 + T cell response to SARS-CoV-2 ( Figure 2D ). With this result, we chose to use our SARS-CoV-2 murine model to identify the SARS-CoV-2-specific CD8 + and CD4 + T cell responses using a peptide library screening method (Figures 3 and 4) . We chose this approach, as it has worked previously for identifying Zika virus (ZIKV) T cell epitopes using a ZIKV peptide library in C57BL/6 mice [36, 48] . Table 1 ). The resulting peptide library was spread across five plates with a total of 269 coronavirus structural peptides, that were screened in the initial studies. To identify the epitope targets of the SARS-CoV-2 specific CD8 + T cells in our primary screen, we followed a similar prime-boost infection strategy detailed in Figure 2A where we delivered hACE2 or GFP mRNA followed by infection with 5x10 4 FFU of SARS-CoV-2. After 21 days, we again transfected mice with hACE2 mRNA followed 24 hours later with 5x10 4 FFU of SARS-CoV-2. At day 5 post SARS-CoV-2 boost, mice were sacrificed and spleens were homogenized into single cell suspensions. The single cell suspensions of splenocytes were plated into 96 well plates and stimulated for six hours in the presence of Brefeldin A (BFA) and either a gene specific peptide pool (Figure 3A) . After the stimulation, splenocytes were stained with the cell surface antibodies, a-CD8, a-CD4, and a-CD19, then stained intracellularly with antibodies against the mouse cytokines interferon gamma (IFN-g) and tumor necrosis factor-a (TNF-a) as shown in Supplemental Figure 2 . To identify antigen experienced CD8 + T cells from the SARS-CoV-2 boosted animals, we compared the results of the peptide stimulation against unstimulated cells and a ZIKV envelope peptide pool as a negative control, and anti-CD3 (clone 45-2C11) stimulated cells as a positive control. Pools that demonstrated an IFN-g response that was more than two-fold over background in the majority of mice screened were brought forward to identify possible SAR-CoV-2 epitopes. Using this approach, it became clear that the majority of the CD8+ T cell response in these H2 b restricted mice targets peptides within the spike and membrane proteins ( Figure 3A) . As demonstrated in Figure 2D , transfection with hACE2 mRNA prior to infection and boost enhanced SARS-CoV-2 specific T cell response. Therefore, for specific epitope identification, hACE2 transfected animals were used moving forward. To further narrow down potential epitope targets, peptides were pooled in an alternative manner in which pools of one to five peptides were generated by combining the same well from each of the five plates from the aliquoted library shown in Supplemental Figure 4 and Supplemental Table 1 and were similarly used to stimulate splenocytes of hACE2 mRNA transfected and SARS-CoV-2 boosted mice ( Figure 3B ). Using this approach 17 well pools screened positive for potential CD8 + T cell epitopes present ( Figure 3B ). Using this information, the peptide pools were deconvoluted and individual multimer peptides from each presumptive positive well was evaluated ( Figure 3C) . The individual peptides within the peptide pools were screened by repeating the hACE2 transfection and SARS-CoV-2 boosting strategy in the Ifnar1 -/mice (Figure 2A) . With this approach, we identified 13 wells that contained peptides which induced a cytokine response that was greater than 2-fold above background in the majority of mice screened ( Table 1) . Using the information from the peptide screen we predicted potential optimal SARS-CoV-2 peptide sequences for each of the epitopes based on known K b and D b anchor residues. Due to the overlapping nature of the screening libraries used, we hypothesize that 8 of the library peptide hits are actually 4 epitopes which are present in multiple wells ( Figure 3D) . To demonstrate that the responses to each peptide were polyfunctional, we assessed IFN-γ and TNF-α expression. All nine of the epitopes we identified were polyfunctional based upon co-expression of both IFN-g and TNF-a in response to stimulation. We named the SARS-CoV-2 peptide epitopes with the abbreviated name of the viral protein The identical approach, using the same mice, was concurrently used to characterize the CD4 + T cell responses to SARS-CoV-2 (Figure 4) . Stimulation of the CD4 + T cells with the gene specific peptide pool ( Figure 4A ) and the pool peptides from the combined five plates (Figure 4B ) showed weak but detectible responses spread across all 12 protein domains evaluated. While the signal to noise ratio of the CD4 + T cell response was lower than what we had observed for the CD8 + T cells, the responses from the protein domains pooled peptides ( Figure 4A ) suggested that the strongest CD4 + T cell response was located in the S2 region of the spike protein, with responses also seen in the RBD and NC pools. Similar to the CD8 + T cell responses, we saw an enhancement of the SARS-CoV-2 specific CD4 + T cell responses as a result of hACE2 mRNA transfection. By evaluating the smaller well pools of peptides consisting of 1-5 pooled peptides, we identified 11 positive wells, where the IFN-g responses to the peptide pool was greater than 2-fold over background in multiple animals ( Figure 4B ). By deconvoluting those wells to individual peptides, we identified six novel SARS-CoV-2 reactive CD4 + T cell epitopes in C57BL/6 mice ( Figure 4C and Table 2) . Similar to what we observed for the peptide stimulated CD8 + T cells, the CD4 + T cells stimulated with the individual peptide epitopes were able to make both IFN-g and TNF-a in response to peptide stimulation ( Figure 4D ). Table 2 : Functional identification of SARS-CoV-2 CD4+ T cell epitopes. H2-b restricted mice were infected with SARS-CoV-2, rested for 30 days and boosted with SARS-CoV-2. At 5 days post boost, splenocytes from 4 mice were harvested and stimulated with peptide or vehicle control in the presence of brefeldin A for 6 hours. Cells were stained for flow cytometry using anti-CD19, CD4, CD8, and IFNγ. CD4+ T cells were defined as CD19 negative, CD8 negative, and CD4 positive. Antigen-specific cells were identified as CD4 T cells producing IFNγ. 1 Peptide sequences are named based on the protein they are contained within, followed by the number of the first amino acid residue of the peptide in the context of the full protein to the last amino acid residue. Sequences contained within the "Spike" peptide library correspond with SARS-CoV Spike due to library availability. 2 Exact amino acid residues of peptide used to stimulate splenocytes. 3 Analogous SARS-CoV-2 peptide name in instances where SARS-CoV peptide library had to be used due to reagent availability. 4 Analogous SARS-CoV-2 peptide sequence in instances where SARS-CoV peptide library had to be used due to reagent availability. 5 Predicted MHC haplotype based on conserved anchor residues. 6 Fold over background frequency of IFNγ+ CD8 T cells. Background is defined as the frequency of IFNγ+ CD4 T cells in a well stimulated with vehicle control. There is a significant gap in our knowledge concerning infection and correlates of protection for coronaviruses, including the novel coronavirus SARS-CoV-2. Much of that deficit is due to the lack of tractable small animal models in which the reagents necessary to study T and B cell responses are available. Our goal was to use an mRNA delivery system to express hACE2, the putative receptor for SARS CoV-2 in mice, to generate a small animal model to study the adaptive immune response to SARS CoV-2 infection. By developing a highly tractable hACE2 expression system, we have generated the potential for an animal model which can be rapidly used by multiple groups to study aspects of disease, transmission, and immune protection for SARS-CoV-2. Importantly, this system is adaptable and has the potential to be employed for use in the rapid development of animal models of emerging infectious diseases which lack necessary host susceptibility factors. In the present study, we utilized this system to understand the adaptive immune response during SARS-CoV-2 infection in Ifnar 1-/mice. We were able to demonstrate that multiple administrations of hACE2-encoding mRNA can be used to detect enhanced CD4 + and CD8 + T cell responses to SARS-CoV-2 during a prime and boost infection (Figure 2) . Additionally, by using this approach in conjunction with an overlapping peptide library to stimulate these T cells, we identified nine SARS-CoV-2 CD8 + T cell epitopes and six CD4 + T cell epitopes which are H2 b restricted. In doing so, we expanded the knowledge within the field of the adaptive immune response to SARS-CoV-2, moving much-needed pre-clinical animal models for SARS-CoV-2 and COVID-19 forward. All animal studies were conducted in accordance with the Guide for Care and Use of Laboratory Animals of the National Institutes of Health and approved by the Saint Louis University Animal Care and Use Committee (IACUC; protocol 2771). GFP and hACE2 expression constructs were cloned by Gibson assembly into a pUC57 vector For anti-CD3 stimulation of peripheral blood lymphocytes, blood was collected via submandibular cheek bleed directly into alkaline lysis buffer. After red blood cell lysis, cells were washed twice with complete RPMI media (10% FBS, 1X HEPES, and 1X beta-mercaptoethanol) and resuspended in complete RPMI. Cells were then split between 2 wells of a 96-well round bottom plate and stimulated for 6 hours at 5% CO2 and 37°C in the presence of 10 μg/ml brefeldin A with 5 μg/ml of anti-CD3 (clone 2C11) or water or a pool of Zika virus envelope peptides as negative controls. For peptide stimulation of splenocytes, spleens were harvested into complete RPMI medium from mice 5 days post SARS-CoV-2 boost. Spleens were ground over a 70μm filter and then washed with 10ml of RPMI. Approximately 5x10 5 cells were plated per well in a 96-well round bottom plate and stimulated for 6 hours at 5% CO2 and 37°C in the presence of 10 μg/ml brefeldin A and 50 μg/ml of each peptide or peptide pools. Following stimulation of lymphocytes, cells were washed once with PBS and stained overnight in PBS at 4°C for the following surface antigens: CD4 (clone RM-4-5), CD8α (clone 53-6.7), and CD19 (clone 1D3). Cells were washed in PBS, then fixed in 2% paraformaldehyde at 4°C for 10 minutes. After fixation, cells were permeabilized with 0.5% saponin and stained in 0.5% saponin at 4°C for 1 hour for the following intracellular antigens: TNFα (clone Mab11) and IFNγ (clone B27). After intracellular staining, cells were washed with 0.5% saponin followed by PBS. The cells were analyzed by flow cytometry using an Attune NxT focusing flow cytometer. For analysis, CD4+ T cells were gated on lymphocytes, CD19 negative, CD4 positive and CD8 negative cells. CD8+ T cells were gated on lymphocytes, CD19 negative, CD4 negative and CD8 positive. Antigen specific cells were then identified as producing IFNγ and/or TNFα at greater than 2-fold over cells stimulated with just a vehicle control. To determine the binding potential of polyclonal sera from SARS-CoV-2 infected mice to the hACE2 receptor binding domain (RBD) of SARS-CoV-2, maxisorp ELISA plates were coated overnight at 4°C with 1 μg/ml of recombinant SARS-CoV-2 RBD protein in carbonate buffer. The following day, the plates were blocked with PBS, 5% BSA, and 0.5% Tween for 2 hours at room temperature prior to being washed. Serum from each mouse was serially diluted and added to each well and allowed to incubate for 1 hour at room temperature prior to being washed. Horseradish peroxidase conjugated goat-antihuman IgG secondary antibody was added and allowed to incubate for 1 hour at room temperature prior to being washed. TMB enhanced substrate was added and allowed to incubate in the dark at room temperature for 15 minutes prior to quenching with 1N HCl. Following quenching, absorbance of the plate was read at 450 nanometers using a BioTek Epoch plate reader. Serum from each mouse was serially diluted in DMEM containing 5% FBS and combined with ~100 focus forming units (FFU) of SARS-CoV-2 and allowed to complex at 37°C and 5% CO2 for 1 hour in a 96-well round bottom plate. The antibody-virus complex was then added to each well of a 96-well flat bottom plate containing a monolayer of Vero WHO cells. Following 1 hour of incubation at 37°C and 5% CO2, the cells were overlayed with 2% methylcellulose and returned to the incubator. After 24 hours of infection, the cells were fixed with 5% electron microscopy grade paraformaldehyde in PBS for 15 minutes at room temperature. The cells adherent to the plate were then rinsed with PBS and permeabilized with 0.05% Triton-X in PBS. Foci of infected Vero cells were stained with anti-SARS polyclonal guinea pig sera (BEI) overnight at 4°C and washed 3 times with 0.05% Triton-X in PBS. Cells were then stained with horseradish peroxidase conjugated goat anti-guinea pig IgG for 2 hours a room temperature. Cells were washed again with 0.05% Triton-X in PBS prior to the addition of TrueBlue KPL peroxidase substrate, which allows the visualization of infected foci as blue spots. The foci were visualized and counted using an ImmunoSpot CTL Elispot plate reader. Figure 4) . In addition, smaller peptide pools were formed by combining analogously oriented wells from each peptide plate (e.g. all A1 peptides are pooled) (Supplemental Figure 4) . Financial support-This work was supported by Table 1 ). Every 12-17-mer peptide came in a lyophilized vial and was reconstituted in 90% DMSO to 10 mg/ml and oriented in a 96 well plate format. Subsets of peptides were consolidated to form 11 peptide pools containing various regions or predicted subdomains of each protein (N-terminal region of S1, receptor binding domain, C-terminal region of S1, S2, N-terminal region of nucleocapsid, RNA binding domain of nucleocapsid, nucleocapsid group 3, dimerization domain of nucleocapsid, Cterminal region of nucleocapsid, envelope, and membrane). To aid in identification, peptide pools of 1-5 peptides were also made consisting of the identical well of each plate (e.g. all A1 wells were pooled). Coronavirus Disease 2019: Clinical Review Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 A pneumonia outbreak associated with a new coronavirus of probable bat origin A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury Attachment factor and receptor engagement of SARS coronavirus and human coronavirus NL63 Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry Recombinant Expression and Characterization of Human and Murine ACE2: Species-Specific Activation of the Alternative Renin-Angiotensin-System Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease Pathogenesis and transmission of SARS-CoV-2 in golden hamsters The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2 Evaluation of K18-hACE2 mice as a model of SARS-CoV-2 infection Lethality of SARS-CoV-2 infection in K18 human angiotensin converting enzyme 2 transgenic mice Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection A Mouse Model of SARS-CoV-2 Infection and Pathogenesis A mouseadapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development Syrian Hamster as an Animal Model for the Study on Coronavirus infection of the central nervous system: hostvirus stand-off Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness Perforin and gamma interferon-mediated control of coronavirus central nervous system infection by CD8 T cells in the absence of CD4 T cells Kinetics of virus-specific CD8+ -T-cell expansion and trafficking following central nervous system infection Mechanisms of central nervous system viral persistence: the critical role of antibody and B cells The Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production by Interfering with TRIM25-Mediated RIG-I Ubiquitination The Conserved Coronavirus Macrodomain Promotes Virulence and Suppresses the Innate Immune Response during Severe Acute Respiratory Syndrome Coronavirus Infection Effects of acute and chronic murine norovirus infections on immune responses and recovery from Friend retrovirus infection CD4+T cells mediate protection against Zika associated severe disease in a mouse model of infection Beta interferon controls West Nile virus infection and pathogenesis in mice Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection A temporal role of type I interferon signaling in CD8+ T cell maturation during acute West Nile virus infection Deficient IFN signaling by myeloid cells leads to MAVS-dependent virus-induced sepsis Human and Murine IFIT1 Proteins Do Not Restrict Infection of Negative-Sense RNA Viruses of the Orthomyxoviridae, Bunyaviridae, and Filoviridae Families Oropouche virus infection and pathogenesis are restricted by MAVS, IRF-3, IRF-7, and type I interferon signaling pathways in nonmyeloid cells Early natural immunity mediated by gamma delta T cells in vaccinia virus (VV) infection A North American H7N3 Influenza Virus Supports Reassortment with 2009 Pandemic H1N1 and Induces Disease in Mice without Prior Adaptation Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein A serological assay to detect SARS-CoV-2 seroconversion in humans Identification of Protective CD8 T Cell Responses in a Mouse Model of Zika Virus Infection The authors declare no competing interest